- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Sheila Frame: Lessons Learned From Launching Zarxio
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses lessons learned from the launch of the company’s biosimilar filgrastim.
Transcript:
Sandoz was the first to launch a biosimilar—Zarxio—in the United States. What are some of the key lessons learned from that product launch?
You know, for Sandoz it's been 35 years' worth of experience developing and selling biopharmaceuticals and biological products. With Zarxio, because it was the first to be launched through the new FDA process with a true biosimilar, we have learned so much, and we've had such incredible success.
It takes a little while, right, for the marketplace to get used to biosimilars. It was pretty new in the United States. But what we've seen in the last couple of years is just incredible excitement in the marketplace about the value that systems can benefit from and reinvest in patient care. So we've had some terrific successes. We've also had some challenges, as you can imagine, right. I mean, it's new for patients. It's new for treatment providers. So we're really excited that we were able to use Zarxio as the first example. It's something that supports patient care from a managing side effects perspective in oncology. It's relatively speaking a short term therapy.
We're really excited. It has been a tremendous opportunity for many physicians, patients, and other healthcare systems. So we've got some great examples now. We've got good publications behind it. I think people are feeling much more comfortable with the value that biosimilars can bring.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
